On this page

Oxiconazole Nitrate

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Oxiconazole Nitrate
Generic name
Oxiconazole Nitrate
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Sun Pharmaceutical Industries, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
2
Packages
7
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Oxiconazole Nitrate 10 mg/g 312139 —

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
9

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Azole Antifungal [EPC] EPC All 44 members
Azoles [CS] CS All 44 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
205076
Application type
ANDA · Abbreviated New Drug Application
Approval date
March 7, 2016
Sponsor
SUN PHARMA CANADA
Products on application
1
Submissions recorded
1
Products approved under application 205076.
Product Trade name Form Strength Ingredient Status TE Flags
205076-001 OXICONAZOLE NITRATE CREAM OXICONAZOLE NITRATE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 205076.
Type No. Action Status Date Review
Original application 1 Approved March 7, 2016 Standard

Review documents

  • 0 · Original application · March 9, 2016
  • 0 · Original application · March 8, 2016

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260128). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260128 HUMAN PRESCRIPTION DRUG · 20250702

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Oxiconazole nitrate cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , or Epidermophyton floccosum . Oxiconazole nitrate cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Oxiconazole nitrate cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which oxiconazole nitrate cream has been shown to be effective rarely occur in children below the age of 12.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Oxiconazole nitrate cream should be applied to affected and immediately surrounding areas once to twice daily in patients with tinea pedis, tinea corporis, or tinea cruris. Oxiconazole nitrate cream should be applied once daily in the treatment of tinea (pityriasis) versicolor. Tinea corporis, tinea cruris, and tinea (pityriasis) versicolor should be treated for 2 weeks and tinea pedis for 1 month to reduce the possibility of recurrence. If a patient shows no clinical improvement after the treatment period, the diagnosis should be reviewed. Note: Tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk that may extend to the neck, arms, and upper thighs. Treatment of the infection may not immediately result in restoration of pigment to the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental sun exposure. Although tinea (pityriasis) versicolor is not contagious, it may recur because the organism that causes the disease is part of the normal skin flora.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Oxiconazole nitrate cream is contraindicated in individuals who have shown hypersensitivity to any of their components.

WARNINGS Oxiconazole nitrate cream, 1% is not for ophthalmic or intravaginal use.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS During clinical trials, of 955 patients treated with oxiconazole nitrate cream , 1%, 41 (4.3%) reported adverse reactions thought to be related to drug therapy. These reactions included pruritus (1.6%); burning (1.4%); irritation and allergic contact dermatitis (0.4% each); folliculitis (0.3%); erythema (0.2%); and papules, fissure, maceration, rash, stinging, and nodules (0.1% each). In a controlled, multicenter clinical trial of 269 patients treated with oxiconazole nitrate lotion , 1%, 7 (2.6%) reported adverse reactions thought to be related to drug therapy. These reactions included burning and stinging (0.7% each) and pruritus, scaling, tingling, pain, and dyshidrotic eczema (0.4% each).

Drug Interactions

openFDA Drug Labeling

Drug Interactions: Potential drug interactions between oxiconazole nitrate and other drugs have not been systematically evaluated.

Drug Interactions: Potential drug interactions between oxiconazole nitrate and other drugs have not been systematically evaluated.

Description

openFDA Drug Labeling

DESCRIPTION Oxiconazole nitrate cream, 1% contains the antifungal active compound oxiconazole nitrate. This formulation is for topical dermatologic use only. Chemically, oxiconazole nitrate is 2 ́,4 ́-dichloro-2-imidazol-1-ylacetophenone ( Z )-[ 0 -(2,4-dichlorobenzyl)oxime], mononitrate. The compound has the molecular formula C 18 H 13 ON 3 CI 4 •HNO 3 , a molecular weight of 492.15, and the following structural formula: Oxiconazole nitrate is a nearly white crystalline powder, soluble in methanol; sparingly soluble in ethanol, chloroform, and acetone; and very slightly soluble in water. Oxiconazole nitrate cream contains 10 mg of oxiconazole per gram of cream in a white to off-white, opaque cream base of purified water USP, white petrolatum USP, stearyl alcohol NF, propylene glycol USP, polysorbate 60 NF, cetyl alcohol NF, and benzoic acid USP, 0.2% as a preservative. chemicalstructure

OVERDOSAGE When 5% oxiconazole cream (5 times the concentration of the marketed product) was applied at a rate of 1 g/kg to approximately 10% of body surface area of a group of 40 male and female rats for 35 days, 3 deaths and severe dermal inflammation were reported. No overdoses in humans have been reported with use of oxiconazole nitrate cream or lotion.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Oxiconazole nitrate cream, 1% is supplied in: 30 g tubes NDC 0168-0358-30, 60 g tubes NDC 0168-0358-60, 90 g tubes NDC 0168-0358-90. Store between 15° and 30°C (59° and 86°F). E. FOUGERA & CO. A division of Fougera PHARMACEUTICALS INC. Melville, New York 11747 46144436A R09/14 #316

Adverse event reports

Source: openFDA FAERS
171
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: OXICONAZOLE NITRATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0168-0358-30 0168-0358 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC 30 g in 1 TUBE (0168-0358-30) March 9, 2016
0168-0358-60 0168-0358 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC 60 g in 1 TUBE (0168-0358-60) March 9, 2016
0168-0358-90 0168-0358 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC 90 g in 1 TUBE (0168-0358-90) March 10, 2016
51672-1359-1 51672-1359 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1359-1) / 15 g in 1 TUBE March 7, 2016
51672-1359-2 51672-1359 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1359-2) / 30 g in 1 TUBE March 7, 2016
51672-1359-3 51672-1359 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1359-3) / 60 g in 1 TUBE March 7, 2016
51672-1359-8 51672-1359 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1359-8) / 90 g in 1 TUBE March 7, 2016
0168-0358 0168-0358 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC — March 9, 2016
51672-1359 51672-1359 Sun Pharmaceutical Industries, Inc. — March 7, 2016

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.